|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RNF187 |
Gene summary for RNF187 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RNF187 | Gene ID | 149603 |
| Gene name | ring finger protein 187 | |
| Gene Alias | RACO-1 | |
| Cytomap | 1q42.13 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q5TA31 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 149603 | RNF187 | C46 | Human | Oral cavity | OSCC | 3.66e-11 | 4.18e-01 | 0.1673 |
| 149603 | RNF187 | C51 | Human | Oral cavity | OSCC | 1.38e-27 | 1.54e+00 | 0.2674 |
| 149603 | RNF187 | C57 | Human | Oral cavity | OSCC | 1.22e-28 | 1.03e+00 | 0.1679 |
| 149603 | RNF187 | C06 | Human | Oral cavity | OSCC | 2.88e-15 | 2.37e+00 | 0.2699 |
| 149603 | RNF187 | C07 | Human | Oral cavity | OSCC | 1.30e-05 | 1.47e+00 | 0.2491 |
| 149603 | RNF187 | C08 | Human | Oral cavity | OSCC | 2.67e-85 | 1.74e+00 | 0.1919 |
| 149603 | RNF187 | C09 | Human | Oral cavity | OSCC | 4.17e-27 | 7.62e-01 | 0.1431 |
| 149603 | RNF187 | LN22 | Human | Oral cavity | OSCC | 5.90e-16 | 1.46e+00 | 0.1733 |
| 149603 | RNF187 | LN38 | Human | Oral cavity | OSCC | 3.21e-04 | 1.06e+00 | 0.168 |
| 149603 | RNF187 | LN46 | Human | Oral cavity | OSCC | 1.74e-03 | 3.82e-01 | 0.1666 |
| 149603 | RNF187 | LP15 | Human | Oral cavity | LP | 2.80e-13 | 1.84e+00 | 0.2174 |
| 149603 | RNF187 | LP17 | Human | Oral cavity | LP | 3.22e-09 | 1.18e+00 | 0.2349 |
| 149603 | RNF187 | SYSMH1 | Human | Oral cavity | OSCC | 1.28e-46 | 1.06e+00 | 0.1127 |
| 149603 | RNF187 | SYSMH2 | Human | Oral cavity | OSCC | 3.25e-26 | 1.04e+00 | 0.2326 |
| 149603 | RNF187 | SYSMH3 | Human | Oral cavity | OSCC | 9.31e-32 | 8.40e-01 | 0.2442 |
| 149603 | RNF187 | SYSMH4 | Human | Oral cavity | OSCC | 4.92e-08 | 2.68e-01 | 0.1226 |
| 149603 | RNF187 | SYSMH5 | Human | Oral cavity | OSCC | 9.78e-15 | 5.27e-01 | 0.0647 |
| 149603 | RNF187 | SYSMH6 | Human | Oral cavity | OSCC | 8.31e-17 | 7.17e-01 | 0.1275 |
| 149603 | RNF187 | P4_S8_cSCC | Human | Skin | cSCC | 4.88e-07 | 1.51e-01 | -0.3095 |
| 149603 | RNF187 | P5_S10_cSCC | Human | Skin | cSCC | 1.04e-11 | 3.19e-01 | -0.299 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00104989 | Breast | Precancer | proteasomal protein catabolic process | 58/1080 | 490/18723 | 1.54e-07 | 8.05e-06 | 58 |
| GO:00431619 | Breast | Precancer | proteasome-mediated ubiquitin-dependent protein catabolic process | 42/1080 | 412/18723 | 2.49e-04 | 3.72e-03 | 42 |
| GO:001049814 | Breast | IDC | proteasomal protein catabolic process | 75/1434 | 490/18723 | 5.59e-09 | 4.41e-07 | 75 |
| GO:004316114 | Breast | IDC | proteasome-mediated ubiquitin-dependent protein catabolic process | 57/1434 | 412/18723 | 9.55e-06 | 2.68e-04 | 57 |
| GO:001049824 | Breast | DCIS | proteasomal protein catabolic process | 75/1390 | 490/18723 | 1.44e-09 | 1.40e-07 | 75 |
| GO:004316124 | Breast | DCIS | proteasome-mediated ubiquitin-dependent protein catabolic process | 57/1390 | 412/18723 | 3.76e-06 | 1.16e-04 | 57 |
| GO:0010498 | Colorectum | AD | proteasomal protein catabolic process | 174/3918 | 490/18723 | 3.18e-14 | 7.66e-12 | 174 |
| GO:0043161 | Colorectum | AD | proteasome-mediated ubiquitin-dependent protein catabolic process | 141/3918 | 412/18723 | 1.77e-10 | 1.68e-08 | 141 |
| GO:0000209 | Colorectum | AD | protein polyubiquitination | 78/3918 | 236/18723 | 8.71e-06 | 2.06e-04 | 78 |
| GO:0070936 | Colorectum | AD | protein K48-linked ubiquitination | 27/3918 | 65/18723 | 1.31e-04 | 1.88e-03 | 27 |
| GO:0051865 | Colorectum | AD | protein autoubiquitination | 28/3918 | 73/18723 | 4.87e-04 | 5.30e-03 | 28 |
| GO:00104981 | Colorectum | SER | proteasomal protein catabolic process | 132/2897 | 490/18723 | 3.08e-11 | 5.55e-09 | 132 |
| GO:00431611 | Colorectum | SER | proteasome-mediated ubiquitin-dependent protein catabolic process | 105/2897 | 412/18723 | 7.48e-08 | 4.70e-06 | 105 |
| GO:00002091 | Colorectum | SER | protein polyubiquitination | 58/2897 | 236/18723 | 1.69e-04 | 3.18e-03 | 58 |
| GO:00104982 | Colorectum | MSS | proteasomal protein catabolic process | 157/3467 | 490/18723 | 2.39e-13 | 5.25e-11 | 157 |
| GO:00431612 | Colorectum | MSS | proteasome-mediated ubiquitin-dependent protein catabolic process | 127/3467 | 412/18723 | 7.70e-10 | 6.32e-08 | 127 |
| GO:00002092 | Colorectum | MSS | protein polyubiquitination | 72/3467 | 236/18723 | 5.19e-06 | 1.42e-04 | 72 |
| GO:00709361 | Colorectum | MSS | protein K48-linked ubiquitination | 27/3467 | 65/18723 | 1.40e-05 | 3.18e-04 | 27 |
| GO:00518651 | Colorectum | MSS | protein autoubiquitination | 25/3467 | 73/18723 | 1.00e-03 | 1.00e-02 | 25 |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RNF187 | SNV | Missense_Mutation | novel | c.436G>A | p.Ala146Thr | p.A146T | Q5TA31 | protein_coding | tolerated(0.83) | probably_damaging(0.988) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RNF187 | SNV | Missense_Mutation | novel | c.520N>A | p.Asp174Asn | p.D174N | Q5TA31 | protein_coding | deleterious(0) | probably_damaging(0.934) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RNF187 | SNV | Missense_Mutation | novel | c.503N>A | p.Arg168Lys | p.R168K | Q5TA31 | protein_coding | tolerated(0.05) | possibly_damaging(0.79) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |